Oculis (NASDAQ:OCS) Receives Buy Rating from HC Wainwright

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 64.65% from the stock’s current price.

Oculis Stock Performance

OCS stock opened at $18.22 on Monday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 12-month low of $10.50 and a 12-month high of $18.40. The stock’s 50 day simple moving average is $16.35 and its 200 day simple moving average is $13.84. The firm has a market cap of $737.98 million, a P/E ratio of -9.44 and a beta of -0.33.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.